Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma

Journal of Clinical Oncology

Volumn 25, Issue 16, 2007, Pages 2230-2235

  Stebbing, Justin ^a   Sanitt, Adam ^a   Teague, Alastair ^a   Powles, Tom ^a   Nelson, Mark ^a   Gazzard, Brian ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD16 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INNATE IMMUNITY; KAPOSI SARCOMA; LABORATORY TEST; MAJOR CLINICAL STUDY; MORTALITY; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE COUNT; MULTIVARIATE ANALYSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD56; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; LYMPHOCYTE COUNT; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, IGG; SARCOMA, KAPOSI; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34250172089     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.7219     Document Type: Article

References (53)

1. Patella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 338:853-860, 1998
2. Sterne JA, Hernan MA, Ledergerber B, et al: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 366:378-384, 2005
3. International Collaboration on HIV and Cancer: Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92:1823-1830, 2000
4. Portsmouth S, Stebbing J, Gill J, et al: A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. Aids 17:F17-F22, 2003
5. Stebbing J, Gazzard B, Mandalia S, et al: Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 22:2177-2183, 2004
6. Friedman-Kien AE, Laubenstein LJ, Rubinstein P, et al: Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 96:693-700, 1982
7. Clifford GM, Polesel J, Rickenbach M, et al: Cancer risk in the Swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425-432, 2005
8. Stebbing J, Sanitt A, Nelson M, et al: A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 367:1495-1502, 2006
9. Stebbing J, Gazzard B, Newsom-Davis T, et al: Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int J Cancer 108:473-474, 2004
10. Stebbing J, Gazzard B, Flore O, et al: Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. Aids 17:1998-2000, 2003
11. Phillips RE, Rowland-Jones S, Nixon DF, et al: Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459, 1991
12. Evans DT, O'Connor DH, Jing P, et al: Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 5:1270-1276, 1999
13. Schmitz JE, Kuroda MJ, Santra S, et al: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860, 1999
14. Wang QJ, Jenkins FJ, Jacobson LP, et al: Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood 97:2366-2373, 2001
15. Wang QJ, Jenkins FJ, Jacobson LP, et al: CD8+ cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and -uninfected individuals. J Infect Dis 182:928-932, 2000
16. Gazzard B, Bernard AJ, Boffito M, et al: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 7:487-503, 2006
17. Gazzard B: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2:1-61, 2005 (suppl 6)
18. Hammer SM, Saag MS, Schechter M, et al: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296:827-843, 2006
19. Andersen P, Gill R: Cox's regression model for counting processes, a large sample study. Annals of Statistics 10:1100-1120, 1982
20. Gill R: Understanding Cox's regression model. Experientia 41:187-199, 1982 (suppl)
21. Venables W, Ripley B: Modern applied statistics with S-PLUS (ed 3rd). New York, NY, Springer, 1999
22. Fleming TR, Lin DY: Survival analysis in clinical trials: Past developments and future directions. Biometrics 56:971-983, 2000
23. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Cox D: Regression models and life tables. J Royal Stat Soc 34:187-220, 1972
25. Mocroft AJ, Johnson MA, Sabin CA, et al: Staging system for clinical AIDS patients: Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Lancet 346:12-17, 1995
26. Turner BJ, Markson L, Taroni F: Estimation of survival after AIDS diagnosis: CD4 T lymphocyte count versus clinical severity. J Clin Epidemiol 49:59-65, 1996
27. Pedersen C, Katzenstein T, Nielsen C, et al: Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: Relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retroviral 16:93-99, 1997
28. Kassa E, Rinke de Wit TF, Hailu E, et al: Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: Association between clinical stages and laboratory markers. Aids 13:381-389, 1999
29. Bower M, Gazzard B, Mandalia S, et al: A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143:265-273, 2005
30. Mounier N, Spina M, Gabarre J, et al: AIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107:3832-3840, 2006
31. Chang Y, Cesarman E, Pessin MS, et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869, 1994
32. Leslie A, Kavanagh D, Honeyborne I, et al: Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 201:891-902, 2005
33. Friedrich TC, Dodds EJ, Yant LJ, et al: Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 10:275-281, 2004
34. Ensoli B, Barillari G, Salahuddin SZ, et al: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345:84-86, 1990
35. Mariotti M, Castiglioni S, Maier JA: Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP. J Cell Biochem 98:301-308, 2006
36. Brander C, O'Connor P, Suscovich T, et al: Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis 184:119-126, 2001
37. Micheletti F, Monini P, Fortini C, et al: Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. Immunology 106:395-403, 2002
38. Stebbing J, Bourboulia D, Johnson M, et al: Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol 77:4306-4314, 2003
39. Wang QJ, Huang XL, Rappocciolo G, et al: Identification of an HLA A*0201-restricted CD8(+) T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood 99:3360-3366, 2002
40. Wilkinson J, Cope A, Gill J, et al: Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol 76:2634-2640, 2002
41. Stebbing J, Gazzard B, Portsmouth S, et al: Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood 102:1806-1814, 2003
42. Stebbing J, Gazzard B, Patterson S, et al: Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: A new approach to therapeutic vaccination. Blood 103:1791-1795, 2004
43. Quinlivan EB, Zhang C, Stewart PW, et al: Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis 185:1736-1744, 2002
44. Engels EA, Biggar RJ, Marshall VA, et al: Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. Aids 17:1847-1851, 2003
45. Marcelin AG, Gorin I, Morand P, et al: Quantification of Kaposi's sarcoma-associated herpesvirus in blood, oral mucosa, and saliva in patients with Kaposi's sarcoma. AIDS Res Hum Retroviruses 20:704-708, 2004
46. Bourboulia D, Aldam D, Lagos D, et al: Short-and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. Aids 18:485-493, 2004
47. Pugliese A, Torre D, Saini A, et al: Cytokine detection in HIV-1/HHV-8 co-infected subjects. Cell Biochem Funct 20:191-194, 2002
48. Sirianni MC, Vincenzi L, Fiorelli V, et al: Gamma-interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: Correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood 91:968-976, 1998
49. Fiorelli V, Gendelman R, Sirianni MC, et al: Gamma-interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: An immune response to human herpesvirus-8 infection? Blood 91:956-967, 1998
50. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006
51. Moir S, Malaspina A, Ogwaro KM, et al: HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 98:10362-10367, 2001
52. Ancuta P, Autissier P, Wurcel A, et al: CD16+ monocyte-derived macrophages activate resting T cells for HIV infection by producing CCR3 and CCR4 ligands. J Immunol 176:5760-5771, 2006
53. Stebbing J, Bower M, Mandalia S, et al: Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin Exp Immunol 145:271-276, 2006